Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Pörssitiedote

Integrum AB: Integrum publishes preliminary revenue, result and cash flow figures for Q3, 2024/2025

Integrum
Lataa tiedote

Mölndal, Sweden - February 18, 2025 -Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today publishes its preliminary revenue, operating profit and cash flow figures for Q3 and May-January 24/25.

Nov-Jan Q3 May-Jan
SEK thousand 2024/25 2023/24 2024/25 2023/24
Net sales, total 23 721 30 108 63 951 78 060
Growth % -21,2% 61,2% -18,1% 39,0%
-US 20 082 20 255 50 344 56 953
Growth % -0,9% 28,8% -11,6% 43,4%
-EMEA/APAC 3 639 9 852 13 606 21 106
Growth % -63,1% 116,4% -35,5% 77,3%
Gross Margin % 81% 90% 81% 83%
EBIT -7 390 340 -30 670 3 869
Cash Flow, Total -19 482 -4 962 -2 248 -13 564
Cash Balance 14 652 30 887 14 652 30 887
S1 Surgeries 44

The difference in revenue compared to the corresponding quarter last year is mainly driven by inventory buildup at distributors in EMEA/APAC previous year.

The difference in cash flow is explained equally by the negative result, increased Account Receivables and R&D investments. The negative figure is the result of low revenue in Q1 2024/25 (May - July). Long times between surgeries and cash collection meant that the low invoicing in Q1 created low inflow of cash in early Q3, which affected the cash flow negatively. More revenue and invoicing in Q3 have increased the Accounts Receivable. This increase will be financed through the Trade term financing agreement during early Q4 and will help improve the cash flow going forward.  

S1 is a new Key Performance Indicator tracking the quarterly number of surgeries where the first component (S1) of the OPRA™ Implant System is implanted. 

All amounts in this press release are preliminary and have not undergone any review by the company auditors.

The complete result for Integrum will be presented in the quarterly report for May - January 2024/25 which is published on March 3, 2025. This means that the company is still in its quiet period.

This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on "Innehållet inom klamrarna kommer ersättas med rätt tid och datum vid utskickstillfället">18-02-2025 17:32 CET.

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.